These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38512387)

  • 21. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study.
    Conget I; Mangas MÁ; Morales C; Caro J; Giménez M; Borrell M; Delgado E
    Diabetes Ther; 2021 Nov; 12(11):2993-3009. PubMed ID: 34599749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose Targets Using Continuous Glucose Monitoring Metrics in Older Adults With Diabetes: Are We There Yet?
    Toschi E; O'Neal D; Munshi M; Jenkins A
    J Diabetes Sci Technol; 2024 Jul; 18(4):808-818. PubMed ID: 38715259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
    Landstedt-Hallin L; Gundgaard J; Ericsson Å; Ellfors-Zetterlund S
    Curr Med Res Opin; 2017 Apr; 33(4):647-655. PubMed ID: 28035840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin Degludec in Adolescents with Type 1 Diabetes: Is Newer Better? - A Retrospective Self-Control Case Series in Adolescents with a History of Diabetic Ketoacidosis.
    Schmitt J; Scott ML
    Horm Res Paediatr; 2019; 92(3):179-185. PubMed ID: 31865335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Continuous Glucose Monitoring Data from a Population with Type 1 Diabetes in South Korea: Nationwide Single-System Analysis.
    Kim JY; Jin SM; Andrade SB; Chen B; Kim JH
    Diabetes Technol Ther; 2024 Jun; 26(6):394-402. PubMed ID: 38277166
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
    Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study.
    Reddy M; Jugnee N; Anantharaja S; Oliver N
    Diabetes Technol Ther; 2018 Nov; 20(11):751-757. PubMed ID: 30265562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of Glycemic Variability in Well-controlled Type 2 Diabetic Patients Using Continuous Glucose Monitoring System.
    Swami V; Yadav SK; Saxena P; Sharma A; Dash CK; Gupta A
    J Assoc Physicians India; 2024 Jan; 72(1):18-21. PubMed ID: 38736069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
    King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
    Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from Intermittently Scanned Continuous Glucose Monitoring to Real-Time Continuous Glucose Monitoring with a Predictive Urgent Low Soon Alert Reduces Exposure to Hypoglycemia.
    Preechasuk L; Avari P; Oliver N; Reddy M
    Diabetes Technol Ther; 2024 Jul; 26(7):498-502. PubMed ID: 38315504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
    Rosenstock J; Cheng A; Ritzel R; Bosnyak Z; Devisme C; Cali AMG; Sieber J; Stella P; Wang X; Frías JP; Roussel R; Bolli GB
    Diabetes Care; 2018 Oct; 41(10):2147-2154. PubMed ID: 30104294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Rizzi A; Tartaglione L; Lucaccini Paoli L; Leo ML; Popolla V; Viti L; Barberio A; Di Leo M; Pontecorvi A; Pitocco D
    Diabetes Obes Metab; 2024 Sep; 26(9):4078-4086. PubMed ID: 39010292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
    Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
    Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial.
    Ruedy KJ; Parkin CG; Riddlesworth TD; Graham C;
    J Diabetes Sci Technol; 2017 Nov; 11(6):1138-1146. PubMed ID: 28449590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.